We reviewed 2019’s top developments in Canadian life sciences IP and regulatory law in our highlights article. Below were our top 10 reads:
#1 Update on biosimilars in Canada – October 2019
#4 Canada releases final amendments to Patented Medicines Pricing Regulations; in force July 1, 2020
#6 Amended PMNOC Regulations: Second Anniversary Update
#7 Federal Court issues two interlocutory decisions in section 8 pregabalin case
#8 Orders of prohibition relating to polymorphic form patent for PRISTIQ upheld on appeal
#9 Federal Court of Appeal confirms obviousness finding in section 8 bortezomib action against Teva
Related Publications & Articles
-
Update on biosimilars in Canada – March 2024
In this article, we provide a further update on developments regarding biosimilars in Canada (approvals, pending submissions, litigation, regulatory, and market access).Read More -
Federal Court of Appeal upholds invalidity of Lilly’s CIALIS patent extending to “physiologically acceptable salt”
The Federal Court of Appeal dismissed an appeal by Lilly from a decision of the Federal Court which had granted a motion for summary trial brought by Teva, Pharmascience, Laboratoire Riva, Apotex and ...Read More -
2024 mid-year highlights in Canadian life sciences IP and regulatory law
In the first half of 2024, Rx IP Update reported on a number of developments in Canadian life sciences IP and regulatory law. The Rx IP Update team at Smart & Biggar has collected the top stories ...Read More